Clinical pharmacology of vasodilator drugs.
Moulds
R F
RF
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers / Q000494:pharmacology; D003327:Coronary Disease / Q000188:drug therapy; D006801:Humans; D006830:Hydralazine / Q000378:metabolism / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy; D007548:Isosorbide Dinitrate / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D005996:Nitroglycerin / Q000378:metabolism / Q000494:pharmacology; D011224:Prazosin / Q000378:metabolism / Q000494:pharmacology; D014665:Vasodilator Agents / Q000378:metabolism / Q000494:pharmacology*; D014700:Verapamil / Q000378:metabolism / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D006830:Hydralazine; D014700:Verapamil; D005996:Nitroglycerin; D007548:Isosorbide Dinitrate; D011224:Prazosin